ALX1
/ KNOW Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 07, 2024
Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer
(PRNewswire)
- "Addition of CMO, Medical Director Chris Polage, MD, and enhancements in clinical operations position Company for success in the clinical development of ALX1 in bronchiectasis....Vast plans to initiate its Phase 1 clinical development program in Q2 2024 and one or more proof-of-concept studies in subjects with bronchiectasis in 2025."
New P1 trial • Non‐Cystic Fibrosis Bronchiectasis
1 to 1
Of
1
Go to page
1